Back to search results

BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)

Abroad (travel likely)RecruitingPHASE2

Conditions

Bronchiolitis Obliterans Syndrome · Bronchiolitis Obliterans · Lung Diseases · Chronic Graft Versus Host Disease

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Stanford University School of Medicine, Stanford, California, United States

    Contact: Study coordinator (Joe L Hsu, MD) · joehsu@stanford.edu
    Contact: Principal Investigator (Joe L Hsu, MD)

  • Dana-Farber Cancer Institute, Boston, Massachusetts, United States

    Contact: Study coordinator (Corey Cutler, MD, MPH) · cscutler@partners.org · 617-632-3470
    Contact: Principal Investigator (Corey Cutler, MD, MPH)

  • Boston Children's Hospital, Boston, Massachusetts, United States

    Contact: Study coordinator (Corey Cutler, MD, MPH) · CSCUTLER@PARTNERS.ORG · 617-632-5946

  • Brigham and Women's Hospital, Boston, Massachusetts, United States

    Contact: Study coordinator (Corey Cutler, MD, MPH) · CSCUTLER@PARTNERS.ORG · 617-632-5946

  • University of Michigan, Ann Arbor, Michigan, United States

    Contact: Study coordinator (Gregory A Yanik, MD, BS) · gyanik@med.umich.edu · 8008651125
    Contact: Principal Investigator (Gregory A Yanik, MD, BS)

  • Fred Hutchinson Cancer Center, Seattle, Washington, United States

    Contact: Study coordinator (Guang-Shing Cheng) · gcheng2@fredhutch.org
    Contact: Principal Investigator (Guang-Shing Cheng, MD)
Study leads

  • Corey Cutler, MD, MPH

    Principal Investigator

    Dana-Farber Cancer Institute

View source on ClinicalTrials.gov(opens in a new tab)